Aduro completes enrollment in CRS-207 and GVAX pancreas cancer vaccine Phase 2 trial

Published on November 30, 2012 at 1:54 AM · No Comments

Aduro BioTech, Inc. announces completion of enrollment in the Phase 2 clinical trial of the sequential administration of two cancer vaccines, Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine, in patients with metastatic pancreatic cancer (ClinicalTrials.gov Identifier: NCT01417000). Enrollment was completed eight months ahead of schedule.

"We believe the rate of enrollment demonstrates significant interest in this vaccine treatment from our clinical investigators and their patients and reflects the high-quality work and dedication of our clinical trial sites," said Dr. Dirk Brockstedt, Senior Vice President of Research and Development at Aduro.

The vaccine regimen has been administered in an outpatient setting and has been well-tolerated thus far with no serious or unexpected adverse events related to the study vaccines. A formal interim analysis of the safety and efficacy of the randomized, controlled trial is expected in the first quarter of next year.

"Metastatic pancreatic cancer is a devastating disease," said Stephen Isaacs, Chairman and Chief Executive Officer of Aduro. "We are optimistic that the results of this trial will reveal a promising new therapeutic option that can extend life and increase quality of life."

Source:

Aduro BioTech, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Clinical trial tests COXEN model in bladder cancer to find promising treatment